Citation Impact
Citing Papers
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
2018 StandoutScienceNobel
Immune Rejection of Mouse Tumors Expressing Mutated Self
2009 StandoutNobel
Intranodal Vaccination with Naked Antigen-Encoding RNA Elicits Potent Prophylactic and Therapeutic Antitumoral Immunity
2010
A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis
2021 StandoutScienceNobel
Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8 + T Lymphocytes
2008 StandoutScienceNobel
Efficient Identification of Mutated Cancer Antigens Recognized by T Cells Associated with Durable Tumor Regressions
2014
Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients
2012
Association of the Autoimmune Disease Scleroderma with an Immunologic Response to Cancer
2013 Science
Exploiting the Mutanome for Tumor Vaccination
2012
Tumor Induction and Tissue Atrophy in Mice Lacking E2F-1
1996
Hallmarks of Cancer: The Next Generation
2011 Standout
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
T cell defined tumor antigens
1997
Progress in human tumour immunology and immunotherapy
2001 Nature
High sensitivity of cancer exome-based CD8 T cell neo-antigen identification
2014
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Inflammation and cancer
2002 StandoutNature
Strategies to overcome immune ignorance and tolerance
2002
Unrestricted cell cycling and cancer
1995
The shared tumor-specific antigen encoded by mouse geneP1A is a target not only for cytolytic T lymphocytes but also for tumor rejection
1998
mRNA vaccines — a new era in vaccinology
2018 StandoutNobel
Tumor Eradication by Adoptive Transfer of Cytototic T Lymphocytes
1992
Analysis of the T cell response to tumor and viral peptide antigens by an IFNγ-ELISPOT assay
1997
A question of balance: the role of cyclin-kinase inhibitors in development and tumorigenesis
1996
mRNA-based cancer vaccine: prevention of B16 melanoma progression and metastasis by systemic injection of MART1 mRNA histidylated lipopolyplexes
2007
Role of ERas in promoting tumour-like properties in mouse embryonic stem cells
2003 StandoutNatureNobel
Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer
1998
Immunization with DNA coding for gp100 results in CD4+ T-cell independent antitumor immunity
2000
Tumor immunity and autoimmunity induced by immunization with homologous DNA.
1998
The Human T Cell Response to Melanoma Antigens
2006
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer
2023
Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts
1998
Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA
1997 StandoutNobel
The Hallmarks of Cancer
2000 Standout
The cancer antigenome
2012
Oncogene-Induced Cell Senescence — Halting on the Road to Cancer
2006
Immunity to Cancer Through Immune Recognition of Altered Self: Studies with Melanoma
2003
Peptides Naturally Presented by MHC Class I Molecules
1993
Cancer vaccines based on the identification of genes encoding cancer regression antigens
1997
Role of the retinoblastoma protein in the pathogenesis of human cancer.
1997 StandoutNobel
The α Chain of the T Cell Antigen Receptor Is Degraded in the Cytosol
1997
The Makings of a Tumor Rejection Antigen
1999
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
2014
Cell Biology of Antigen Processing and Presentation to Major Histocompatibility Complex Class I Molecule-Restricted T Lymphocytes
1992
Sources of diversity in T cell epitope discovery
2011
Genetic immunization of mice with human tyrosinase-related protein 2: Implications for the immunotherapy of melanoma
2000
Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential
2015 StandoutNobel
Tumor‐specific shared antigenic peptides recognized by human T cells
2002
MHC ligands and peptide motifs: first listing
1995
The Cytoplasmic Tail of the Mouse Brown Locus Product Determines Intracellular Stability and Export from the Endoplasmic Reticulum
1998
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
2014
Optimization of a self antigen for presentation of multiple epitopes in cancer immunity
2006
A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation
1999
Influenza virus-infected dendritic cells stimulate strong proliferative and cytolytic responses from human CD8+ T cells.
1994 StandoutNobel
Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses
2002
Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study
2017
Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
1996
Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a
1997 Standout
Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling
1998
T cell-recognized antigenic peptides derived from the cellular genome are not protein degradation products but can be generated directly by transcription and translation of short subgenic regions. A hypothesis
1989
Taking dendritic cells into medicine
2007 StandoutNatureNobel
mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma
2016
Sorting and Secretion of a Melanosome Membrane Protein, gp75/TRP1
1997
E2F-1 Functions in Mice to Promote Apoptosis and Suppress Proliferation
1996 StandoutNobel
TAP off - tumors on
1997
p53 Deficiency Rescues the Adverse Effects of Telomere Loss and Cooperates with Telomere Dysfunction to Accelerate Carcinogenesis
1999 StandoutNobel
Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity
2014
Spinning molecular immunology into successful immunotherapy
2002
Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy
1998
Translation of genomics-guided RNA-based personalised cancer vaccines: towards the bedside
2014
Short Dysfunctional Telomeres Impair Tumorigenesis in the INK4aΔ2/3 Cancer-Prone Mouse
1999 StandoutNobel
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
2015 StandoutNature
Cancer/testis antigens, gametogenesis and cancer
2005 Standout
Cancer vaccines
1998
Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes
1992
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
2012 StandoutNatureNobel
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade
2017 StandoutNobel
A genetically humanized mouse model for hepatitis C virus infection
2011 StandoutNatureNobel
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
2016
A common E2F-1 and p73 pathway mediates cell death induced by TCR activation
2000 StandoutNatureNobel
Dendritic cells and the control of immunity
1998 StandoutNatureNobel
Structure of the gene of tum− transplantation antigen P91A: The mutated exon encodes a peptide recognized with Ld by cytolytic T cells
1989
Role of the INK4a Locus in Tumor Suppression and Cell Mortality
1996
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
2015 Nature
Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma
1997
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Autoimmunity and tumor immunity induced by immune responses to mutations in self
2006
T-cell responses of vaccinated cancer patients
2003
mRNA Cancer Vaccines
2016
Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.
1994
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.
1994
The Class I Antigen-processing Pathway for the Membrane Protein Tyrosinase Involves Translation in the Endoplasmic Reticulum and Processing in the Cytosol
1998
Detection of self-reactive CD8 + T cells with an anergic phenotype in healthy individuals
2014 StandoutScienceNobel
Systematic identification of signaling pathways with potential to confer anticancer drug resistance
2014
Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70
2000 StandoutNobel
Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity
2014
A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma
1991 StandoutScience
Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia
2014
Individually distinct transplantation antigens of chemically induced mouse tumors
1988
Regulation of Receptor Fate by Ubiquitination of Activated β 2 -Adrenergic Receptor and β-Arrestin
2001 StandoutScienceNobel
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma
1999 StandoutNobel
Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes.
1994
Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine.
2001 StandoutNobel
Human Tumor Antigens and Cancer Immunotherapy
2015
Cancer Cell Cycles
1996 StandoutScience
CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen.
1991
HLA-Binding Properties of Tumor Neoepitopes in Humans
2014
Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
2003
Increased Antigen Presentation Efficiency by Coupling Antigens to MHC Class I Trafficking Signals
2008
Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene.
1994
Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes
1998
Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family.
1999
The Immunodominant Antigen of an Ultraviolet-induced Regressor Tumor Is Generated by a Somatic Point Mutation in the DEAD Box Helicase p68
1997
Database of T cell-defined human tumor antigens: the 2013 update.
2013
Identification of the Genes Encoding Cancer Antigens: Implications for Cancer Immunotherapy
1996
Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity
2006 StandoutNobel
A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes
2022 StandoutScienceNobel
The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice.
1991
Effector Function of Human Tumor-Specific CD8 T Cells in Melanoma Lesions: A State of Local Functional Tolerance
2004
RNA-Based Vaccines in Cancer Immunotherapy
2015
Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas.
1990
Aerobic Copper-Catalyzed Organic Reactions
2013 Standout
UBIQUITIN AND THE CONTROL OF PROTEIN FATE IN THE SECRETORY AND ENDOCYTIC PATHWAYS
1998
Epitope Landscape in Breast and Colorectal Cancer
2008 StandoutNobel
The future of immune checkpoint therapy
2015 StandoutScienceNobel
Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors
1997 StandoutNobel
Mutated PPP1R3B Is Recognized by T Cells Used To Treat a Melanoma Patient Who Experienced a Durable Complete Tumor Regression
2013
Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines
2016
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.
1994
Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells
1993 StandoutScienceNobel
Detection of T cell responses to a ubiquitous cellular protein in autoimmune disease
2014 StandoutScienceNobel
Identification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes
1996
HUMAN T CELL RESPONSES AGAINST MELANOMA
2005
Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells
2006
Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning
2004
Immunotherapy: Bewitched, Bothered, and Bewildered No More
2004 StandoutScienceNobel
Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein.
1995
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.
1994
Hepatitis C Virus Envelope Glycoprotein E1 Originates in the Endoplasmic Reticulum and Requires Cytoplasmic Processing for Presentation by Class I MHC Molecules
1999 StandoutNobel
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.
1996
Neoantigens in cancer immunotherapy
2015 StandoutScience
Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes
1998
A unique tumor antigen produced by a single amino acid substitution
1995
Introduction of a Glycosylation Site into a Secreted Protein Provides Evidence for an Alternative Antigen Processing Pathway: Transport of Precursors of Major Histocompatability Complex Class I–Restricted Peptides from the Endoplasmic Reticulum to the Cytosol
1997
Adoptive T cell therapy using antigen-specific CD8+T cell clones for the treatment of patients with metastatic melanoma:In vivopersistence, migration, and antitumor effect of transferred T cells
2002
Ectopic expression of dE2F and dDP induces cell proliferation and death in the Drosophila eye.
1996
Coupling and Uncoupling of Tumor Immunity and Autoimmunity
1999
Integrating Genetic Approaches into the Discovery of Anticancer Drugs
1997 StandoutScienceNobel
Personalized vaccines for cancer immunotherapy
2018 Science
THE UBIQUITIN SYSTEM
1998 StandoutNobel
Serological analysis of human tumor antigens: molecular definition and implications
1997
Structure of the gene of tum- transplantation antigen P35B: presence of a point mutation in the antigenic allele.
1990
Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 Melanoma
1997
Point Mutation in Essential Genes with Loss or Mutation of the Second Allele
2001
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
2009 StandoutScience
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
2002 StandoutNobel
Induction of HIV-1 gag specific immune responses by cationic micelles mediated delivery of gag mRNA
2015
Structure of the gene of tum- transplantation antigen P198: a point mutation generates a new antigenic peptide.
1990
Works of Thomas Wölfel being referenced
The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8+ T lymphocytes in IFN-γ ELISPOT assays
2002
Quantification of CD8+T Lymphocytes Responsive to Human Immunodeficiency Virus (HIV) Peptide Antigens in HIV‐Infected Patients and Seronegative Persons at High Risk for Recent HIV Exposure
1998
Inhibitory Effect of RNA Pool Complexity on Stimulatory Capacity of RNA-pulsed Dendritic Cells
2008
Effective induction of anti-melanoma immunity following genetic vaccination with synthetic mRNA coding for the fusion protein EGFP.TRP2
2005
Genes Coding for Tumor Antigens Recognized by Human Cytolytic T Lymphocytes
1993
Lysis of human pancreatic adenocarcinoma cells by autologous hla‐class I‐restricted cytolytic T‐lymphocyte (CTL) clones
1993
The use of computer-assisted video image analysis for the quantification of CD8+ T lymphocytes producing tumor necrosis factor α spots in response to peptide antigens
1997
Cloning and characterization of genes coding for tum− transplantation antigens
1989
Analysis of antigens recognized on human melanoma cells by A2‐restricted cytolytic t lymphocytes (CTL)
1993
Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
2012 Nature
Isolation of naturally processed peptides recognized by cytolytic T lymphocytes (CTL) on human melanoma cells in association with HLA‐A2.1
1994
A tyrosinase nonapeptide presented by HLA‐B44 is recognized on a human melanoma by autologous cytolytic T lymphocytes
1996
An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer
2007
Two tyrosinase nonapeptides recognized on HLA‐A2 melanomas by autologous cytolytic T lymphocytes
1994
Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor α in response to HLA-A2.1-binding melanoma and viral peptide antigens
1996
Cellular immune response to human renal‐cell carcinomas: Definition of a common antigen recognized by HLA‐A2‐restricted cytotoxic T‐Lymphocyte (CTL) clones
1994
A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.
1994
Lysis of human melanoma cells by autologous cytolytic T cell clones. Identification of human histocompatibility leukocyte antigen A2 as a restriction element for three different antigens.
1989
Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation.
1988
Cytotoxic T-lymphocyte clones from different patients display limited T-cell-receptor variable-region gene usage in HLA-A2-restricted recognition of the melanoma antigen Melan-A/MART-1.
1995
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.
1993
Monitoring of Anti-Vaccine CD4 T Cell Frequencies in Melanoma Patients Vaccinated with a MAGE-3 Protein
2005
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens
2005
Transporter (TAP)- and proteasome-independent presentation of a melanoma-associated tyrosinase epitope
2000
An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins.
1996
Immunogenic (tum−) variants obtained by mutagenesis of mouse mastocytoma P815
1987
A p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
1995 Science
Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma.
1997
Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection.
1989